A5035223374- Spondyloarthritis Studies and Treatments
- Rheumatoid Arthritis Research and Therapies
- Psoriasis: Treatment and Pathogenesis
- Bone and Joint Diseases
- Autoimmune and Inflammatory Disorders Research
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Inflammasome and immune disorders
- Systemic Lupus Erythematosus Research
- Liver Disease Diagnosis and Treatment
- Diabetes Management and Education
- Health Policy Implementation Science
- Chronic Disease Management Strategies
Netherlands Institute for Health Services Research
2023
Amsterdam UMC Location Vrije Universiteit Amsterdam
2016-2022
Amsterdam University Medical Centers
2019-2021
University Medical Center
2021
University Hospital and Clinics
2021
Vrije Universiteit Amsterdam
2020
Reade
2017
Center for Rheumatology
2016
To assess gender differences in ankylosing spondylitis (AS) patients relation to tumor necrosis factor alpha inhibitor (TNFi) drug survival and occurrence of adverse events daily practice a large peripheral hospital.Retrospective data were collected from AS treated with etanercept, infliximab adalimumab between January 2004 2014. Kaplan-Meier curves conducted describe the time.Overall, 122 (60.7% male) included over 10-year time period, mean treatment period 51 months (1-127 months). In...
The aim of this cohort study was to evaluate the long-term effects TNF inhibitors (TNFis) on BMD and incidence vertebral fractures (VFxs) in patients with ankylosing spondylitis (AS). Consecutive active AS TNFi treatment duration up 4 years available DXA scans spine X-rays were included. (classified according WHO criteria for osteoporosis) hip lumbar spine, VFx as a Genant score >1/>20% height loss), radiological progression (modified stoke spinal [mSASSS]) scores obtained at baseline...
To investigate the efficacy of 16-week treatment with etanercept (ETN) in patients suspected nonradiographic axial spondyloarthritis (SpA).Tumor necrosis factor inhibitor-naive inflammatory back pain at least 2 SpA features and high disease activity (Bath Ankylosing Spondylitis Disease Activity Index score ≥4), without requirement a positive finding on magnetic resonance imaging (MRI) sacroiliac (SI) joint and/or elevated C-reactive protein (CRP) level, were randomized (1:1) to receive ETN...
Abstract Objectives The primary aim is to evaluate signs of inflammation on MRI sacroiliac joints (SIJ)/spine in inflammatory back pain (IBP) patients suspected nr-axSpA with high disease activity. Secondary aims are describe the onset new lesions at after 6 months and gender differences presence inflammation. Method Consecutively, IBP least two spondyloarthritis features, activity (BASDAI ≥ 4), who were TNFi naïve, had a SIJ spine. In absence active lesions, was repeated months. images...
Objective To investigate the distribution of patient-reported outcomes (PROs) in patients with axial spondyloarthritis (axSpA) initiating a tumor necrosis factor inhibitor (TNFi), to assess proportion reaching PRO “remission” across registries and treatment series, compare registered fulfill modified New York (mNY) criteria for ankylosing spondylitis (AS) vs nonradiographic axSpA (nr-axSpA). Methods Fifteen European contributed scores pain, fatigue, patient global assessment (PtGA), Bath...
Objective To assess sex differences in response, level of disease activity, and drug survival tumour necrosis factor inhibitor (TNFi)-naïve ankylosing spondylitis (AS) patients.Method Consecutive AS patients, fulfilling the modified New York criteria, were included a prospective cohort study at initiation first TNFi followed until this medication was stopped (drug survival). Disease activity scores [AS Activity Score using C-reactive protein (ASDAS-CRP), Bath Index (BASDAI), CRP] measured 3,...
Objective Physical function in patients with axial spondyloarthritis (axSpA) is currently evaluated through questionnaires. The Ankylosing Spondylitis Performance Index (ASPI) a performance-based measure for physical functioning, which has been validated Dutch radiographic (r−) axSpA. interrater reliability not yet determined. To our knowledge, this study the first to evaluate validity, reliability, and feasibility of ASPI another patient population, including both r− nonradiographic (nr−)...
<h3>Background</h3> Limited data are available on the influence of gender and lifestyle factors, such as smoking, alcohol consumption Body Mass Index (BMI) disease activity response to TNF inhibitors (TNFi) in ankylosing spondylitis (AS). <h3>Objectives</h3> This study aimed determine whether these factors age at diagnosis, TNFi. <h3>Methods</h3> In a prospective study, clinical (age, gender, C-reactive protein, Ankylosing Spondylitis Disease Activity Score (ASDAS), Bath (BASDAI), Functional...
<h3>Background</h3> Accumulating data revealed difference in treatment efficacy biologicals women with axial spondyloartritis (axSpA) (1). <h3>Objectives</h3> The aim of this study was to assess gender differences TNF inhibitor response up a five year biological <h3>Methods</h3> Radiographic axSpA patients (AS) were recruited from the Amsterdam Spondyloarthritis cohort (the AmSpA cohort) VU University center and Reade. This prospective, observational included consecutive AS who treated...
Objective To study the long-term effect of 16 weeks etanercept treatment on disease activity and radiographic changes in patients with suspected non-radiographic axial spondyloarthritis (nr-axSpA).Method Eighty inflammatory back pain nr-axSpA, a Bath Ankylosing Disease Activity Index (BASDAI) ≥ 4, received (n = 40) 25 mg twice weekly or placebo for weeks. They were followed without restrictions after 24 weeks, up to 3 years. Comparisons made between who first period, BASDAI, Spondylitis...
Background: Despite the new classification criteria for non-radiographic axial spondyloarthritis (nr-axSpA) patients according to Assessment of Spondyloarthritis International Society (ASAS), there are limited data on disease progression in nr-axSpA patients. Objectives: First assess improvement activity suspected after 16 weeks treatment with Etanercept (ETN) or Placebo (PBO). Second, changes active inflammation MRI SI-joints (SIJ) between ETN and PBO group 24 without study medication....
<h3>Objectives</h3> To determine adverse events and treatment survival of TNF alpha inhibiting in ankylosing spondylitis patients a large peripheral hospital daily practice compare these results with data other studies (1-3). <h3>Methods</h3> A retrospective study design was conducted where user characteristics treated etanercept, infliximab adalimumab the period January 2004 until 2014 Kennemer Gasthuis were collected. Statistical analyses performed Kaplan Meijer curves to describe drug...
<h3>Background</h3> Lifestyle related factors, such as smoking and Body Mass Index (BMI) are known to increase the disease activity progression in rheumatoid arthritis (1,2). In ankylosing spondylitis (AS), only a few studies available regarding this topic (3–5). Smoking was associated with an earlier diagnosis of AS, higher (OR=2.5) doubled increased radiographic compared non smokers. addition, alcohol consumption having physical demanding occupation were more axial lesions. A BMI lower...